Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients.

British journal of clinical pharmacology - 1 Mar 2003

Lee How Sung, Goh Boon Cher, Fan Lu, Khoo Yok Moi, Wang Lingzhi, Lim Robert, Ong Ai Bee, Chua Charlotte

Abstract excerpt

AIMS: To investigate CYP3A activity in cancer and noncancer Asian patients using midazolam and to reveal possible alternative traits for phenotyping CYP3A. METHODS: Intravenous midazolam 2.5 mg or 2.5-8 mg was administered to 27 cancer and 24 noncancer patients, respectively. Plasma was sampled at 0, 0.25, 0.5, 1, 1.5, 2, 3.5 and 5 h after intravenous ultrashort, 30 s infusion. Plasma midazolam and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Asia

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Chromatography, High Pressure Liquid

Share to Cytochrome P-450 CYP3A

Share to Half-Life

Share to Infusions, Intravenous

Share to Midazolam

Share to Oxidoreductases, N-Demethylating

Source

Open in PubMed Open full text

Identifiers

PMID: 12630977
DOI: 10.1046/j.1365-2125.2003.01767.x
PMCID: PMC1884211

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients.PMID 12630977Read ↗

Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.Semantic proximity Read ↗

CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients.Semantic proximity Read ↗

Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques.Semantic proximity Read ↗

CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.Semantic proximity Read ↗

Limited sampling strategy of partial area under the concentration-time curves to estimate midazolam systemic clearance for cytochrome P450 3A phenotyping.Semantic proximity Read ↗

CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.Semantic proximity Read ↗

Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes.Semantic proximity Read ↗

Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam.Semantic proximity Read ↗

In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration.Semantic proximity Read ↗

Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping.Semantic proximity Read ↗

Functional Characterization of 40 CYP3A4 Variants by Assessing Midazolam 1'-Hydroxylation and Testosterone 6β-Hydroxylation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.